Pyxis Oncology (PYXS) Assets (2020 - 2026)

Pyxis Oncology (PYXS) has reported Assets for 7 consecutive years, with $54.9 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Assets fell 55.43% year-over-year to $54.9 million in Q2 2026; TTM through Jun 2026 was $54.9 million, a 55.43% decrease from a year earlier, with the FY2025 full-year figure at $91.5 million, down 41.77% from the prior year.
• Assets was $54.9 million for Q2 2026 at Pyxis Oncology, down from $91.5 million in the prior quarter.
• Over five years, Assets peaked at $252.7 million in Q1 2022 and troughed at $54.9 million in Q2 2026.
• A 5-year average of $173.0 million and a median of $182.8 million in 2023 frame the typical range for Assets.
• Across the five-year window, Assets soared 60.51% in 2022 and plunged 55.43% in 2026, its largest moves.
• Over 5 years, Assets stood at $211.4 million in 2022, then decreased by 17.81% to $173.7 million in 2023, then decreased by 9.52% to $157.2 million in 2024, then tumbled by 41.77% to $91.5 million in 2025, then plunged by 39.99% to $54.9 million in 2026.
• The last three Assets figures came in at $54.9 million (Q2 2026), $91.5 million (Q4 2025), and $105.6 million (Q3 2025), per Business Quant data.